<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Pharma — September 2022]]></title><description><![CDATA[<p dir="auto">Teva: Studies Show Efficacy Of Fremanezumab In Patients With Migraine And Major Depressive Disorder <a href="https://www.proinvestor.com/investornyt/876299/teva-studies-show-efficacy-of-fremanezumab-in-patients-with-migraine-and-major-depressive-disorder" rel="nofollow ugc">https://www.proinvestor.com/investornyt/876299/teva-studies-show-efficacy-of-fremanezumab-in-patients-with-migraine-and-major-depressive-disorder</a></p>
]]></description><link>https://dev.proinvestor.com/forum/topic/400866/pharma-september-2022</link><generator>RSS for Node</generator><lastBuildDate>Sun, 07 Jun 2026 16:26:30 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/400866.rss" rel="self" type="application/rss+xml"/><pubDate>Thu, 08 Sep 2022 05:30:53 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Pharma — September 2022 on Fri, 09 Sep 2022 03:53:38 GMT]]></title><description><![CDATA[<p dir="auto">Lundbeck/SHB: Ser lav mulighed for Rexulti-succes i agitation <a href="https://www.proinvestor.com/investornyt/876854/lundbeck-shb-ser-lav-mulighed-for-rexulti-succes-i-agitation" rel="nofollow ugc">https://www.proinvestor.com/investornyt/876854/lundbeck-shb-ser-lav-mulighed-for-rexulti-succes-i-agitation</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037628</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037628</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Fri, 09 Sep 2022 03:53:38 GMT</pubDate></item></channel></rss>